Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 8195-8200

  Wu, Licun ^a   Tannock, Ian F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; BROXURIDINE; CYCLIN D1; CYTOSTATIC AGENT; FLUOROURACIL; PACLITAXEL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GROWTH INHIBITION; HIGH RISK PATIENT; HORMONE RESPONSE; IMPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; BROMODEOXYURIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; PIPERIDINES; RECEPTORS, ESTROGEN; THIOPHENES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 28144446988     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1258     Document Type: Article

References (20)

1. Gelber RD, Cole BF, Goldhirsch A, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996;347: 1066-71.
2. Albain KS, Green SJ, Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc ASCO 2002;21:37a.
3. Davis AJ, Tannock IF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 2000;1:86-93.
4. Kim JJ, Tannock IF. Repopulation of cancer cells during radiotherapy and chemotherapy: an important cause of treatment failure. Nat Rev Cancer 2005;5: 516-25.
5. Begg AC, Hofland I, Kummermehr J. Tumour cell repopulation during fractionated radiotherapy: correlation between flow cytometrtc and radiobiological data in three murine tumours. Eur J Cancer 1991;27: 537-43.
6. Petersen C, Zips D, Krause M, et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys 2001;51:483-93.
7. Wu L, Tannock IF. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res 2003; 63:2134-8.
8. Schafer JM, Lee ES, Dardes RC, et al. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts. Clin Cancer Res 2001;7:2505-12.
9. Buzdar A, O'Shaughnessy JA, Booser DJ, et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 2003;21: 1007-14.
10. Wu L, Tannock IF. Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. Clin Cancer Res 2003;9:4614-8.
11. Noel A, De Pauw-Gillet MC, Purnell G, Nusgens B, Lapiere CM, Foidart JM. Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer 1993;68:909-15.
12. Mullen P, Ritchie A, Langdon SP, Miller WR. Effect of Matrigel on the tumorigenecity of human breast and ovarian carcinoma cell lines, Int J Cancer 1996;67: 816-20.
13. Zhu XL, Hartwick W, Rohan T, Kandel R. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma. Mod Pathol 1998;11:1082-8.
14. Gillett C, Smith P, Gregory W, et al. Cyclin D1 and prognosis in human breast cancer Int J Cancer 1996; 69:92-9.
15. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998;52:1-15.
16. Castro-Rivera E, Samudio I, Safe S. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 2001;276:30853-61.
17. Detre S, Riddler S, Salter J, et al. Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model. Cancer Res 2003;63:6516-22.
18. Freddie CT, Larsen SS, Bartholomussen M, et al. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells. Mol Cell Endocrinol 2004;219:27-36.
19. Tamaki T, Naomoto Y, Kimura S, et al. Apoptosis in normal tissues induced by anti-cancer drugs. J Int Med Res 2003;31:6-16.
20. van Laar JA, Durrani FA, Rustum YM. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2′-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26. Cancer Res 1993;53: 1560-4.